ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

Journal of Hepatology

Volumn 49, Issue 6, 2008, Pages 985-997

  Jasinghe, Viraj J ^a   Xie, Zhigang ^a   Zhou, Jianbiao ^a   Khng, Jiaying ^a   Poon, Lai Fong ^a   Senthilnathan, Palaniyandi ^a   Glaser, Keith B ^d   Albert, Daniel H ^d   Davidsen, Steven K ^d   Chen, Chien Shing ^a,b,c,e  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d ABBOTT LABORATORIES   (United States)

^e LOMA LINDA UNIVERSITY   (United States)

Author keywords

ABT 869; Angiogenesis; Hepatocellular carcinoma; mTOR pathway; Rapamycin; Tyrosine kinase inhibitor

Indexed keywords

ABT 869; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL HUH7; CANCER CELL SK HEP 1; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CELL CULTURE; CELL MIGRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDAZOLES; LIVER NEOPLASMS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; SIROLIMUS; SUBCUTANEOUS FAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 55549129243     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.08.010     Document Type: Article

References (55)

1. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90 (2000) 1562-1569
2. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
3. Taylor-Robinson S.D., Foster G.R., Arora S., Hargreaves S., and Thomas H.C. Increase in primary liver cancer in the UK, 1979-94. Lancet 350 (1997) 1142-1143
4. Deuffic S., Poynard T., Buffat L., and Valleron A.J. Trends in primary liver cancer. Lancet 351 (1998) 214-215
5. Nagasue N., Kohno H., Chang Y.C., Taniura H., Yamanoi A., Uchida M., et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 217 (1993) 375-384
6. Houben K.W., and McCall J.L. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 5 (1999) 91-95
7. Nagasue N., Uchida M., Makino Y., Takemoto Y., Yamanoi A., Hayashi T., et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 105 (1993) 488-494
8. Yamamoto J., Kosuge K., Takayama T., Shimada K., Yamasaki S., Ozaki H., et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83 (1996) 1219-1222
9. Poon R.T., Fan S.T., Lo C.M., Liu C.L., and Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229 (1999) 216-222
10. Thomas M.B. Hepatocellular carcinoma: the need for progress. J Clin Oncol 23 (2005) 2892-2899
11. Fausto N., and Webber E.M. Control of liver growth. Crit Rev Eukaryot Gene Expr 3 (1993) 117-135
12. Ito Y., Sasaki Y., Horimoto M., Wada S., Tanaka Y., Kasahara A., et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27 (1998) 951-958
13. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
14. Semenza G.L. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54 (2003) 17-28
15. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
16. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., and Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 (1998) 68-77
17. Poon R.T., Ng I.O., Lau C., Yu W.C., Fan S.T., and Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182 (2001) 298-304
18. Yoshiji H., Kuriyama S., Hicklin D.J., Huber J., Yoshii J., Miyamoto Y., et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30 (1999) 1179-1186
19. Ng I.O.L., Poon R.T.P., Lee J.M.F., Fan S.T., Ng M., and Tso W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in Hepatocellular Carcinoma. Am J Clin Pathol 116 (2001) 838-845
20. Poon R.T., Ng I.O., Lau C., Zhu L.X., Yu W.C., Lo C.M., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233 (2001) 227-235
21. Poon R.T., Lau C.P., Cheung S.T., Yu W.C., and Fan S.T. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 63 (2003) 3121-3126
22. Albert D.H., Tapang P., Magoc T.J., Pease L.J., Reuter D.R., Wei R.Q., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5 (2006) 995-1006
23. Guo J., Marcotte P.A., McCall J.O., Dai Y., Pease L.J., Michaelides M.R., et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 5 (2006) 1007-1013
24. Shankar D., Li J., Tapang P., McCall J.O., Pease L.J., Dai Y., et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukaemia. Blood 109 (2007) 3400-3408
25. Zhou J., Pan M., Xie Z., Loh S.L., Bi C., Tai Y.C., et al. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 22 (2007) 138-148
26. Zhou J., Khng J., Jasinghe V.J., Bi C., Neo C.H.S., Pan M., et al. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leukemia Res 32 (2008) 1091-1100
27. Mita M.M., Mita A., and Rowinsky E.K. The molecular target of rapamycin (m-TOR) as a therapeutic target against cancer. Cancer Biol Ther 2 (2003) S169-S177
28. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
29. Vezina C., Kudelski A., and Sehgal S.N. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 8 (1975) 721-726
30. Marte R.R., Klicius J., and Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55 (1997) 48-51
31. Eng C.P., Sehgal S.N., and Vezina C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibiot (Tokyo) 37 (1984) 1231-1237
32. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (London) 369 (1994) 756-758
33. Lorenz M.C., and Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 270 (1995) 27531-27537
34. Blume-Jensen P., and Hunter T. Oncogenic kinase. Nature (London) 411 (2001) 355-365
35. Hara K., Yonezawa K., Kozlowski M.T., Sugimoto T., Andrabi K., Weng Q.P., et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272 (1997) 26457-26463
36. Price D.J., Grove J.R., Calvo V., Avruch J., and Bierer B.E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (Washington, DC) 257 (1992) 973-977
37. Chung J., Kuo C.J., Crabtree G.R., and Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69 (1992) 1227-1236
38. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
39. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004) 8421-8425
40. Xu G., Zhang W., Bertram P., Zheng X.F., and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24 (2004) 893-900
41. Schumacher G., Oidtmann M., Rueggeberg A., Jacob D., Jonas S., Langrehr J.M., et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11 (2005) 1420-1425
42. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., and Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7 (2005) R1097-R1110
43. deGraffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10 (2004) 8059-8067
44. Goudar R.K., Shi Q., Hjelmeland M.D., Keir S.T., McLendon R.E., Wikstrand C.J., et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4 (2005) 101-112
45. Xie Z., Choong P.F., Poon L.F., Zhou J., Khng J., Jasinghe V.J., et al. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62 (2008) 949-957
46. Poon R.T., Ng I.O., Lau C., Yu W., Yang Z., Fan S., et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20 (2002) 1775-1785
47. Law B.K., Chytil A., Dumont N., Hamilton E.G., Waltner-Law M.E., Aakre M.E., et al. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 22 (2002) 8184-8198
48. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
49. Jones M.K., Wang H., Peskar B.M., Levin E., Itani1 R.M., Sarfeh I.J., et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5 (1999) 1418-1423
50. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 (2006) 11851-11858
51. Morabito A., De Maio E., Di Maio M., Normanno N., and Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11 (2006) 753-764
52. Boffa D.J., Thomas F.L.D., Yang H., Sharma V.K., Lagman M., and Suthanthiran M. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 10 (2004) 293-300
53. Semela D., Piguet A.C., Kolev M., Schmitter K., Hlushchuk R., Djonov V., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46 (2007) 840-848
54. Dutcher J.P. Mammalian target of rapamycin inhibition. Clin Cancer Res 10 (2004) 6383s-6387s
55. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193